Get the Stockscreener App
2.76
6.76%
-0.20
After Hours:
2.84
0.08
+2.90%
Ovid Therapeutics Inc stock is traded at $2.76, with a volume of 3.99M.
It is down -6.76% in the last 24 hours and up +40.10% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$2.96
Open:
$2.97
24h Volume:
3.99M
Relative Volume:
1.39
Market Cap:
$416.84M
Revenue:
$7.25M
Net Income/Loss:
$-17.41M
P/E Ratio:
-10.51
EPS:
-0.2627
Net Cash Flow:
$-38.33M
1W Performance:
+6.15%
1M Performance:
+40.10%
6M Performance:
+67.27%
1Y Performance:
+863.69%
1-Day Range:
$2.73
$2.99
1-Week Range:
$2.65
$3.105
52-Week Range:
$0.2615
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.76 | 447.05M | 7.25M | -17.41M | -38.33M | -0.2627 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Roth Capital | Buy |
| Nov-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-08-25 | Resumed | B. Riley Securities | Buy |
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
OVID Reiterated by Wedbush -- Price Target Maintained at $7.00 - GuruFocus
Leerink reiterates Ovid Therapeutics stock rating on KCC2 potential By Investing.com - Investing.com South Africa
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS DisordersSlideshow - Seeking Alpha
Value Recap: What hedge funds are buying Ovid Therapeutics Inc2026 Analyst Calls & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
VIX Spike: Does Ovid Therapeutics Inc have declining or rising EPS2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
Whale Trades: What are Ovid Therapeutics Incs growth levers2026 Gainers & Low Volatility Stock Recommendations - baoquankhu1.vn
OVID Should I Buy - Intellectia AI
H.C. Wainwright raises Ovid Therapeutics stock price target to $4 By Investing.com - Investing.com Australia
[Form 4] Ovid Therapeutics Inc. Insider Trading Activity - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) director granted RSUs in lieu of cash pay - Stock Titan
Director Kevin Fitzgerald awarded Ovid Therapeutics (OVID) RSU compensation - Stock Titan
OVID.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Trade Recap: Why is Ovid Therapeutics Inc stock going up2026 Top Gainers & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Ovid Therapeutics Surge: Positive Phase 1 Data Ignites Market Confidence - timothysykes.com
Ovid Therapeutics (OVID): HC Wainwright & Co. Raises Price Targe - GuruFocus
H.C. Wainwright raises Ovid Therapeutics stock price target to $4 - Investing.com
Big Money Moves: Why is Ovid Therapeutics Inc stock going up - baoquankhu1.vn
Ovid Therapeutics Inc. (OVID) stock price, news, quote and history - Yahoo Finance UK
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 - The Manila Times
Ovid Therapeutics Shares Surge After Positive Phase 1 Results and Financing News - StocksToTrade
Earnings Report: Is Ovid Therapeutics Inc being accumulated by smart money2026 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Ovid Therapeutics Inc (OVID) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
OVID.O Technical Analysis & Stock Price Forecast - Intellectia AI
OVID News & Events - intellectia.ai
IPO Launch: Does Ovid Therapeutics Inc have declining or rising EPSWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn
Gains Report: Can Ovid Therapeutics Inc maintain its current growth rate2026 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Ovid Therapeutics (OVID) price target increased by 14.29% to 4.87 - MSN
Rate Hike: Is Ovid Therapeutics Inc still a buy after recent gains2026 Chart Watch & High Accuracy Trade Alerts - baoquankhu1.vn
OVID Therapeutics Inc (NASDAQ:OVID) Passes Minervini's High-Growth Momentum and Trend Template Filters - ChartMill
Aug Reactions: How does Ovid Therapeutics Inc score in quality rankingsCEO Change & Weekly Stock Performance Updates - baoquankhu1.vn
Aug Big Picture: Does Ovid Therapeutics Inc have declining or rising EPSBuy Signal & Weekly Momentum Stock Picks - baoquankhu1.vn
Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Ovid spikes as Wedbush moves to Outperform on lead asset - MSN
Lifesci Capital Has Negative Estimate for OVID Q1 Earnings - MarketBeat
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Ovid Therapeutics (NASDAQ: OVID) chair exercises 47,333-share warrant at $1.40 - Stock Titan
Investors pour $60M into Ovid Therapeutics to advance seizure drugs - Crain's New York Business
Ovid Therapeutics' new epilepsy trial data ignites rally - MSN
Ovid Therapeutics secures $60M funding to advance epilepsy drug programs - MSN
If You Invested $1,000 in Ovid Therapeutics Inc (OVID) - Stock Titan
Here's why Ovid Therapeutics stock popped higher today - MSN
Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to Hold - MarketBeat
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma - MSN
Ovid Therapeutics Stock Surges on Positive Drug Trial Data and Financing Plans - StocksToTrade
Ovid Shares Surge with Positive Phase 1 Results and Strategic Moves - timothysykes.com
Wedbush Forecasts Strong Price Appreciation for Ovid Therapeutics (NASDAQ:OVID) Stock - MarketBeat
Ovid Therapeutics (OVID) Sees Price Target Raised by Wedbush | O - gurufocus.com
Bond Watch: How does Ovid Therapeutics Inc score in quality rankingsMarket Performance Report & Daily Technical Forecast Reports - baoquankhu1.vn
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding - Seeking Alpha
Here's Why Ovid Therapeutics Stock Popped Higher Today - AOL.com
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):